X

DOXYMYCIN-100 CAPSULE 100mg

Product Information

Registration Status: Active

SIN02205P

DOXYMYCIN-100 CAPSULE 100mg is approved to be sold in Singapore with effective from 1988-06-29. It is marketed by BEACONS PHARMACEUTICALS PTE LTD, with the registration number of SIN02205P.

This product contains Doxycycline 100mg in the form of CAPSULE. It is approved for ORAL use.

This product is manufactured by BEACONS PHARMACEUTICALS PTE LTD in SINGAPORE.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Product Reference
Loading...


Description

A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum).

Indication

Doxycycline is indicated for use in respiratory tract infections caused by Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Legionella spp., or Klebsiella spp. It is also used for prophylaxis of malaria. Doxycycline is indicated for a variety of bacterial infections, from Mycobacterium fortuitum and M. marinum, to susceptible E. coli and Brucella spp. It can be used as an alternative to treating plague, tetanus, Campylobacter fetus

Mechanism of Action

Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis. Doxycycline prevents the normal function of the apicoplast of Plasmodium falciparum, a malaria causing organism.

Pharmacokinetics

Absorption
Completely absorbed following oral administration.
Distribution
Metabolism
Hepatic
Elimination

Toxicity

Symptoms of overdose include anorexia, nausea, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions (with monilial overgrowth) in the anogenital region, skin reactions such as maculopapular and erythematous rashes, exfoliative dermatitis, photosensitivity, hypersensitivity reactions such as urticaria, angioneurotic oedema, anaphylaxis, anaphyl-actoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus, benign intracranial hypertension in adults disappearing on discontinuation of the medicine, haematologic abnormalities such as haemolytic anaemia, thrombocytopenia, neutropenia, and eosinophilia. LD50=262 mg/kg (I.P. in rat).

Active Ingredient/Synonyms

5-hydroxy-α-6-deoxytetracycline | 6-alpha-deoxy-5-oxytetracycline | 6alpha-deoxy-5-oxytetracycline | 6α-deoxy-5-oxytetracycline | Anhydrous doxycycline | Doxiciclina | Doxycyclin | Doxycycline (anhydrous) | Doxycycline anhydrous | Doxycyclinum | Doxycycline |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!